TGTX · Company research
TG Therapeutics, Inc. (TGTX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
23records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance | TG Therapeutics, Inc. (TGTX) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 17, 2026 | neutral | 0 | 0.6 |
| Tg Therapeutics Stock Price Forecast. Should You Buy TGTX? - StockInvest.us | Tg Therapeutics Stock Price Forecast. Should You Buy TGTX? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - The Globe and Mail | TGTX Stock Rises 60% in 6 Months: Here's What You Should Know The Globe and Mail | View source ↗ | The Globe and Mail | Oct 13, 2026 | neutral | 0 | 0.6 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - Zacks Investment Research | TGTX Stock Rises 60% in 6 Months: Here's What You Should Know Zacks Investment Research | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 0.6 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - TradingView | TGTX Stock Rises 60% in 6 Months: Here's What You Should Know TradingView | View source ↗ | TradingView | Oct 13, 2026 | neutral | 0 | 0.6 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know | TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know | TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - TradingView | TGTX Stock Rises 60% in 6 Months: Here's What You Should Know TradingView | View source ↗ | TradingView | Oct 13, 2026 | neutral | 0 | 0.6 |
| Thermo Fisher to Report Q3 Earnings: What's in the Cards? | Thermo Fisher Scientific is set to report Q3 2026 results on October 21, with consensus estimates projecting 7.1% revenue growth to $11.91B and 10.5% EPS growth to $6.40. The company's Life Sciences Solutions and Laboratory Products segments are expected to drive growth at 10.1% and 9.8% respectively, supported by recent product innovations. However, Specialty Diagnostics revenues are projected to decline 3% following the sale of its microbiology business to Astorg for $1.075 billion. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.6 | 1 |
| Thermo Fisher to Report Q3 Earnings: What's in the Cards? | Thermo Fisher Scientific is set to report Q3 2026 results on October 21, with consensus estimates projecting 7.1% revenue growth to $11.91B and 10.5% EPS growth to $6.40. The company's Life Sciences Solutions and Laboratory Products segments are expected to drive growth at 10.1% and 9.8% respectively, supported by recent product innovations. However, Specialty Diagnostics revenues are projected to decline 3% following the sale of its microbiology business to Astorg for $1.075 billion. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.6 | 1 |
| TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data - Stocktwits | TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| A five-year analysis estimated disability progression at 9.4% with BRIUMVI, versus 17.9% with ofatumumab - Stock Titan | A five-year analysis estimated disability progression at 9.4% with BRIUMVI, versus 17.9% with ofatumumab Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| TG Therapeutics (NasdaqCM:TGTX) Stock Forecast & Analyst Predictions - Simply Wall Street | TG Therapeutics (NasdaqCM:TGTX) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow - Yahoo Finance | TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| First results from a cell therapy for progressive multiple sclerosis are scheduled for Oct. 23. - Stock Titan | First results from a cell therapy for progressive multiple sclerosis are scheduled for Oct. 23. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| TG Therapeutics (TGTX) Stock May Be Below Fair Value As BRIUMVI Gains Share - Simply Wall Street | TG Therapeutics (TGTX) Stock May Be Below Fair Value As BRIUMVI Gains Share Simply Wall Street | View source ↗ | Simply Wall Street | Sep 25, 2026 | neutral | 0 | 0.6 |
| TGTX Stock Outperforms 95% of Stocks. Here's Why. - Investor's Business Daily | TGTX Stock Outperforms 95% of Stocks. Here's Why. Investor's Business Daily | View source ↗ | Investor's Business Daily | Aug 24, 2026 | neutral | 0 | 0.6 |
| TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics - Barchart.com | TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics Barchart.com | View source ↗ | Barchart.com | Aug 21, 2026 | neutral | 0 | 0.6 |
| TG Therapeutics (TGTX) Stock Sinks As Profit Shrinks Behind BRIUMVI Growth - Simply Wall Street | TG Therapeutics (TGTX) Stock Sinks As Profit Shrinks Behind BRIUMVI Growth Simply Wall Street | View source ↗ | Simply Wall Street | Aug 4, 2026 | neutral | 0 | 0.6 |
| TG Therapeutics (TGTX) Stock May Be Undervalued As Revenue Guidance Rises - Yahoo Finance | TG Therapeutics (TGTX) Stock May Be Undervalued As Revenue Guidance Rises Yahoo Finance | View source ↗ | Yahoo Finance | Aug 4, 2026 | neutral | 0 | 0.6 |
| Why TG Therapeutics (TGTX) Stock Is Down Today - Quiver Quantitative | Why TG Therapeutics (TGTX) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 3, 2026 | neutral | 0 | 0.6 |
| TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch - Stocktwits | TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch Stocktwits | View source ↗ | Stocktwits | Jul 8, 2026 | neutral | 0 | 0.6 |
| TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News - Yahoo Finance | TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News Yahoo Finance | View source ↗ | Yahoo Finance | Jul 8, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.